Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
20 studies found for:    "methodist hospital" | Open Studies | "Urogenital Neoplasms" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
2 Recruiting HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Conditions: Human Papillomavirus-Related Carcinoma;   Human Papillomavirus Positive Oropharyngeal Carcinoma;   Human Papillomavirus Positive Cervical Carcinoma;   Human Papillomavirus Positive Anal Carcinoma;   Human Papillomavirus Positive Vulvar Carcinoma;   Human Papillomavirus Positive Penile Carcinoma
Intervention: Genetic: HPV Specific T Cells
3 Recruiting TAA-Specific CTLS for Solid Tumors (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
4 Recruiting Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer
Condition: Localized Prostate Cancer
Intervention: Drug: Ad5-SGE-REIC/Dkk3
5 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
6 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
7 Recruiting Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Brenner Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Behavioral: Behavioral Dietary Intervention;   Behavioral: Compliance Monitoring;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
8 Recruiting Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
Interventions: Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
9 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive Side Effects of Cancer Therapy;   Psychological Impact of Cancer;   Radiation Toxicity;   Sexual Dysfunction and Infertility;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
10 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy
11 Recruiting Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Conditions: Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen Citrate;   Drug: Topotecan Hydrochloride;   Drug: Trametinib
12 Recruiting Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Condition: Cervical Cancer
Interventions: Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
13 Recruiting S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Methotrexate;   Drug: Vinblastine;   Drug: Doxorubicin;   Drug: Filgrastim
14 Recruiting Study of Kidney Tumors in Younger Patients
Conditions: Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
15 Recruiting Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
Conditions: Ovarian Granulosa Cell Tumor;   Ovarian Gynandroblastoma;   Ovarian Sertoli-Leydig Cell Tumor;   Ovarian Sex Cord Tumor With Annular Tubules;   Ovarian Sex Cord-Stromal Tumor;   Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types;   Ovarian Steroid Cell Tumor
Interventions: Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
16 Recruiting Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Lymphedema;   Sexual Dysfunction and Infertility;   Stage IA1 Cervical Cancer;   Stage IA2 Cervical Cancer;   Stage IB1 Cervical Cancer
Interventions: Procedure: Conization;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Therapeutic Conventional Surgery;   Procedure: Therapeutic Lymphadenectomy
17 Recruiting A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Condition: Carcinoma, Renal Cell
Interventions: Drug: tivozanib hydrochloride;   Drug: Sorafenib
18 Recruiting Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasms
Interventions: Biological: Vigil;   Biological: Placebo
19 Recruiting Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: Dalantercept and axitinib;   Drug: Placebo and axitinib
20 Recruiting Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza

Study has passed its completion date and status has not been verified in more than two years.